Article Text

Download PDFPDF

European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015
  1. Andreas du Bois, MD, PhD,
  2. Alexander Reuss,
  3. Eric Pujade-Lauraine, MD,
  4. Sandro Pignata, MD,
  5. Jonathan Ledermann, MD,
  6. Antonio Casado, MD,
  7. Jalid Sehouli, MD,
  8. Mansoor Mirza, MD,
  9. Nicoletta Colombo, MD,
  10. Christian Marth, MD,
  11. Els Witteveen, MD,
  12. Jose Del Campo, MD,
  13. Paula Calvert, MD,
  14. Gerassimos Aravantinos, MD,
  15. Mehmet Ali Vardar, MD,
  16. Ate G.J. van der Zee, MD,
  17. Jacob Korach, MD,
  18. Cagatay Taskiran, MD,
  19. Mathias Fehr, MD,
  20. Ros Glasspool, MD,
  21. Jacobus Pfisterer, MD,
  22. David Cibula, MD, PhD and
  23. Ignace Vergote, MD, PhD
  1. European Network of Gynaecological Oncological Trial Groups, Geneva, Switzerland.
  1. Address correspondence and reprint requests to Andreas du Bois, MD, PhD, ENGOT Office, Rue François-Versonnex 7, PO Box 1726, 1207 Geneva, Switzerland. E-mail: engot{at}esgo.org.

Abstract

Abstract The first version of ENGOT’s Requirements for Trials Between Academic Groups and Industry Partners in Europe was published 2010. This first update integrates the experiences made by the ENGOT network and the cooperative group studies while performing, analyzing, and publishing -among others - three large phase III trials. Furthermore, progress in European legislation and its impact on clinical studies in Europe have been considered in this update process.

  • Academic groups
  • ENGOT
  • Requirements
  • Trials

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.